Avalanche Biotechnologies, Inc.
Avalanche Biotechnologies, Inc. is listed today as Avalanche Biotechnologies: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2024 | $128 M | No. 4 | $50 to $250 million | equity, options | SEC | |
| Aug 2014 | $10 M | No. 3 | $10 to $50 million | equity | SEC | |
| Apr 2014 | $55 M | No. 2 | $50 to $250 million | equity | SEC | |
| Sep 2010 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Avalanche Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).
SEC Form D · Feb 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2024
That is all the official record says: Avalanche Biotechnologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Avalanche Biotechnologies, Inc. are on record.
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Deerfield Special Situations International Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Hans Hull | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2014) | SEC Form 3 |
| Mark S. Blumenkranz | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Regeneron Pharmaceuticals, Inc. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Steven Daniel Schwartz | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Thomas W. Chalberg | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Venrock Associates VI, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Healthcare Capital Partners LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Management VI, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Partners Management VI, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Partners VI, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| VHCP Co-Investment Holdings, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| VHCP Management, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Zygtech, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 45 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kishor Peter Soparkar | Executive officer | Feb 2024 |
| Laurent Fischer | Executive officer | Feb 2024 |
| Linda Rubinstein | Executive officer | Feb 2024 |
| Setareh Gurses Seyedkazemi | Executive officer | Feb 2024 |
| Hans Hull | Executive officer | Sep 2014 |
| Linda Bain | Executive officer | Sep 2014 |
| Mehdi Gasmi | Executive officer | Sep 2014 |
| Thomas Chalberg | Executive officer | Sep 2014 |
| Thomas W. Chalberg | Executive officer | Apr 2014 |
| C. David Nicholson | Director | Feb 2024 |
| Dawn Gurses Svoronos | Director | Feb 2024 |
| James Gurses Scopa | Director | Feb 2024 |
| Laurent Fischer | Director | Feb 2024 |
| Mark Lupher | Director | Feb 2024 |
| Patrick Machado | Director | Feb 2024 |
| Rabia Gurses Ozden | Director | Feb 2024 |
| Reed Gurses Tuckson | Director | Feb 2024 |
| Scott Gurses Whitcup | Director | Feb 2024 |
| Soo Hong | Director | Feb 2024 |
| John McLaughlin | Director | Sep 2014 |
| Mark Blumenkranz | Director | Sep 2014 |
| Paul Wachter | Director | Sep 2014 |
| Steven Schwartz | Director | Sep 2014 |
| Thomas Chalberg | Director | Sep 2014 |
| John D. McLaughlin | Director | Apr 2014 |
| Mark S. Blumenkranz | Director | Apr 2014 |
| Paul D. Wachter | Director | Apr 2014 |
| Steven D. Schwartz | Director | Apr 2014 |
| Thomas W. Chalberg | Director | Apr 2014 |
| Steven D. Schwarz | Director | Nov 2013 |
About
American gene therapy company.